The Next Era in the Management of Metastatic Colorectal Cancer

To participate in this activity, please:

Log in Sign Up

Greater understanding of the pathology of colorectal cancer has led to the integration of targeted treatment options. But not all targeted treatment options are the same, necessitating thoughtful selection of guideline-recommended therapy in collaboration with the patient. Stacey Cohen, MD, explores the significance of molecular profiling and tumor markers in personalizing immunotherapy for metastatic colorectal cancer. She also delves into the evolving landscape of targeted therapies, discussing the nuances and considerations of different options to optimize patient outcomes.

Course Credit:

0.50 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2024-08-19
Closes: 2025-08-19

Target Audience:

Oncologists, pathologists, oncology nurse practitioners, nurses and physician associates; pharmacists and other healthcare professionals involved in the care of patients diagnosed with metastatic colorectal cancer (mCRC).

This activity is supported by an independent educational grant from Taiho Oncology, Inc.

Accreditation Information

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Alexa Basilio, PharmD, BCOP (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Stacey A. Cohen, MD

    Fred Hutchinson Cancer Center
    Associate Professor, Clinical Research Division, Fred Hutch
    Associate Professor, Division of Hematology and Oncology, University of Washington School of Medicine
    Seattle, Washington

Learning Objectives

  • Assess the unmet medical needs in patients with mCRC with current therapies.
  • Summarize the safety, tolerability, and efficacy of the available targeted therapies for the treatment of patients with mCRC.
  • Construct individualized treatment plans with a focus on targetable mutations for the treatment of patients with mCRC based on current guidelines.

Faculty Disclosures

Stacey A. Cohen, MD

Advisory Board: Agenus, AbbVie, Eisai, Guardant, Merck, Regeneron, Taiho
Consultant: Pfizer
Data Monitoring Safety Board: GSK